Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial
Open Access
- 7 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10), 3216
- https://doi.org/10.3390/jcm9103216
Abstract
The PRO-C6 assay, a reflection of collagen type VI synthesis, has been proposed as a non-invasive early biomarker of kidney fibrosis. We aimed to investigate cross-sectional and longitudinal associations between plasma and urine PRO-C6 and proven histological changes after kidney transplantation. The current study is a post-hoc analysis of 94 participants of the MECANO trial, a 24-month prospective, multicenter, open-label, randomized, controlled trial aimed at comparing everolimus-based vs. cyclosporine-based immunosuppression. PRO-C6 was measured in plasma and urine samples collected 6 and 24 months post-transplantation. Fibrosis was evaluated in biopsies collected at the same time points by Banff interstitial fibrosis/tubular atrophy (IF/TA) scoring and collagen staining (Picro Sirius Red; PSR); inflammation was evaluated by the tubulo-interstitial inflammation score (ti-score). Linear regression analyses were performed. Six-month plasma PRO-C6 was cross-sectionally associated with IF/TA score (Std. β = 0.34), and prospectively with 24-month IF/TA score and ti-score (Std. β = 0.24 and 0.23, respectively) (p < 0.05 for all). No significant associations were found between urine PRO-C6 and any of the biopsy findings. Fibrotic changes and urine PRO-C6 behaved differentially over time according to immunosuppressive therapy. These results are a first step towards non-invasive fibrosis detection after kidney transplantation by means of collagen VI synthesis measurement, and further research is required.Funding Information
- Danish Research Fund (Na)
- Novartis Pharma (Na)
This publication has 35 references indexed in Scilit:
- Urinary endotrophin predicts disease progression in patients with chronic kidney diseaseScientific Reports, 2017
- Non-invasive quantification of collagen turnover in renal transplant recipientsPLOS ONE, 2017
- Urinary collagen degradation products as early markers of progressive renal fibrosisJournal of Translational Medicine, 2017
- Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue DiseasesPossibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue FailureASSAY and Drug Development Technologies, 2013
- Renal interstitial fibrosisCurrent Opinion in Nephrology and Hypertension, 2012
- Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent EraAmerican Journal of Transplantation, 2004
- PROTOCOL RENAL ALLOGRAFT BIOPSIES AND THE DESIGN OF CLINICAL TRIALS AIMED TO PREVENT OR TREAT CHRONIC ALLOGRAFT NEPHROPATHY1Transplantation, 2000
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantThe New England Journal of Medicine, 1999
- Urinary and serum type II collagen: markers of renal fibrosisNephrology Dialysis Transplantation, 1997
- A study of the quality of life and cost-utility of renal transplantationKidney International, 1996